Abstract
Objectives: Cardiovascular disease is the most common cause of sickness and death for long-term kidney transplant recipients, and dyslipidemia is an important risk factor for developing cardiovascular disease. Lipid-lowering strategies, with the use of statins, have been shown to reduce the cardiovascular risks related to dyslipidemia, but concomitant use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and immuno - suppressive agents may increase the risk of rhabdomyolysis owing to a drug-drug interaction. We report a case of simvastatin-induced rhabdo - myolysis and acute kidney injury triggered by addition of sirolimus and cisplatin-based chemo - therapy to a kidney transplant recipient who had previously tolerated chronic statin therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 152-155 |
| Number of pages | 4 |
| Journal | Experimental and Clinical Transplantation |
| Volume | 12 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 2014 |
Keywords
- Cisplatin
- Kidney transplant
- Rhabdomyolysis
- Simvastatin
- Sirolimus